San Francisco, California Terence Friedlander, MD:consultant/advisor/speaker:AADI Biosciences, Astellas, AstraZeneca, EMD Serono, Merck, Seagen. Rana R. McKay, MD Professor of Medicine and Urology Moores Cancer Center University of California San Diego ...
Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024 TOKYO, Jan 16, 2024 - (JCN Newswire) -Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Fr...
Nasdaq: TLX, Telix, the Company) today announces presentations featuring the Company’s late-stage and next generation therapeutic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025) to be held in San Francisco, CA...
2025年美国临床肿瘤学会泌尿生殖系统癌症研讨会(ASCO-GU)将于2025年2月13日至15日在旧金山举行,GU 癌症研讨会旨在为与会者提供对 GU 恶性肿瘤诊断、治疗和研究中最及时主题的深入、多学科分析。癌症护理和研究界的所有成员都将受益于研讨会对该领域最新科学及其临床应用的探索。在这次多学科研讨会上,世界知名的教职...
FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025. Vimseltinib Is Now Approved For Symptomatic Tenosynovial Giant Cell Tumor Vimseltinib (DCC-3014) has received FDA approval for the treatment of symptom...
Genitourinary (GU) Cancers Symposium is a three-day scientific and educational meeting designed to meet the needs of physicians and other members of the ca. ASCO Genitourinary Cancers Symposium 2026 is held in San Francisco CA, United States, from 2/26/2
ASCO Genitourinary Cancers Symposium Dates: TBD Venue: Moscone Center,San Francisco CA,United States Genitourinary (GU) Cancers Symposium is a three-day scientific and educational meeting designed to meet the needs of physicians and other members of the cancer care and research community who diagnose...
◆ 会议地点:美国 旧金山(San Francisco) ◆ 会议简介: 2026年ASCO泌尿生殖系统肿瘤研讨会(ASCO-GU2026)将于2026年2月26-28日在美国加利福尼亚州旧金山举行。ASCO泌尿生殖系统肿瘤研讨会是一个为期三天的科学和教育会议,旨在满足医生和其他诊断、治疗和研究GU恶性肿瘤相关专业人士的需要。泌尿生殖道肿瘤研讨会由美国...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted its supplemental new drug application (sNDA) and granted Priority Review designation for KERENDIA® (finerenone) for the treatment of adult patients with heart failure (HF) with...